Medpace (MEDP) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Medpace (MEDP) over the past year, gaining 166.3% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with -53.3% for OABI. Medpace is the larger company by market cap ($17.11 billion vs $689.2 million), about 24.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MEDP | OABI |
|---|---|---|
| Share price | $613.15 | $4.74 |
| Market cap | $17.11B | $689.15M |
| 1-day change | +1.73% | +1.71% |
| YTD return | +7.31% | +151.89% |
| 1-year return | +13.50% | +166.29% |
| 5-year return | +222.16% | -53.26% |
| P/E ratio (TTM) | 36.00 | — |
| Forward P/E | 31.74 | — |
| EPS (TTM) | $17.03 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.53B | — |
| Revenue growth (YoY) | +19.97% | — |
| Net income (latest FY) | $451.12M | — |
| Operating margin | 21.14% | — |
| Net margin | 17.83% | — |
| 52-week high | $677.90 | $5.43 |
| 52-week low | $373.00 | $1.30 |
| Distance from 52-week high | -9.55% | -12.71% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -3.47% | +75.74% |
| Average volume | 272.38K | 1.47M |
| Shares outstanding | 27.91M | 145.39M |
| Employees | 6,500 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medpace is about 24.8 times larger than OmniAb by market value ($17.11B vs $689.15M).
- OABI has outperformed MEDP by 152.8 percentage points over the past year.
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
MEDP vs OABI FAQ
Which is bigger, Medpace or OmniAb?
Medpace (MEDP) is larger, with a market capitalization of $17.11B compared with $689.15M for OmniAb (OABI).
Which stock has performed better over the past year, MEDP or OABI?
OABI returned +166.29% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Are Medpace and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.